{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(1)"],"submitter":["Hatanaka T"],"pubmed_abstract":["<h4>Aims</h4>This retrospective study compared the survival between elderly and non-elderly patients.<h4>Methods</h4>A total of 5545 treatment-naive patients with hepatocellular carcinoma (HCC) who visited 7 different hospitals from January 2000 to December 2018 were included. Patients ≥80 years old were defined as elderly patients. We divided the patients into three groups based on the timing of the initial treatment: Early, middle, and late periods defined as 2000 to 2005, 2006 to 2012, and 2013 to 2018, respectively.<h4>Results</h4>There were 132 (8.9%), 405 (17.5%), and 388 (22.2%) elderly patients in the early, middle, and late period, respectively, showing a significant increase over time (p < 0.001). In both elderly and non-elderly patients, the median albumin-bilirubin score signif"],"journal":["Cancer medicine"],"pagination":["345-357"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9844645"],"repository":["biostudies-literature"],"pubmed_title":["The prognosis of elderly patients with hepatocellular carcinoma: A multi-center 19-year experience in Japan."],"pmcid":["PMC9844645"],"pubmed_authors":["Tada T","Kosaka H","Hiraoka A","Ishikawa T","Imai M","Real-life Practice Experts for HCC (RELPEC) Study Group","Nagano T","Shibata H","Takaguchi K","Tsuji K","Toyoda H","Itobayashi E","Shimada N","Nouso K","Naganuma A","Tanaka T","Tsutsui A","Kumada T","Kakizaki S","Hatanaka T","Yasuda S","Nakamura S","Kaibori M","Kariyama K"],"additional_accession":[]},"is_claimable":false,"name":"The prognosis of elderly patients with hepatocellular carcinoma: A multi-center 19-year experience in Japan.","description":"<h4>Aims</h4>This retrospective study compared the survival between elderly and non-elderly patients.<h4>Methods</h4>A total of 5545 treatment-naive patients with hepatocellular carcinoma (HCC) who visited 7 different hospitals from January 2000 to December 2018 were included. Patients ≥80 years old were defined as elderly patients. We divided the patients into three groups based on the timing of the initial treatment: Early, middle, and late periods defined as 2000 to 2005, 2006 to 2012, and 2013 to 2018, respectively.<h4>Results</h4>There were 132 (8.9%), 405 (17.5%), and 388 (22.2%) elderly patients in the early, middle, and late period, respectively, showing a significant increase over time (p < 0.001). In both elderly and non-elderly patients, the median albumin-bilirubin score signif","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-18T18:17:48.517Z","creation":"2025-04-07T05:54:28.37Z"},"accession":"S-EPMC9844645","cross_references":{"pubmed":["35608226"],"doi":["10.1002/cam4.4850"]}}